设为首页 加入收藏

TOP

VFEND 200 mg powder for solution for infusion Voriconazole
2014-12-28 17:36:39 来源: 作者: 【 】 浏览:367次 评论:0

For doctors

 

What is it and how is it used?

VFEND belongs to a group of medicines called triazole antifungal agents. These medicines are used to treat a wide variety of fungal infections. VFEND works by killing or stopping the growth of the fungi that cause infections.

What fungal infections are treated with VFEND?
VFEND is used to treat serious fungal infections caused by Aspergillus, Scedosporium, Fusarium, fluconazole-resistant Candida, and candidaemia in patients with normal white blood cell counts.

This product should only be used under the supervision of a doctor.
VFEND is mainly for use in seriously ill patients.

What do you have to consider before using it?

Do not take VFEND:

It is very important that you inform your doctor or pharmacist if you are taking or have taken any other medicines, even those that are obtained without a prescription. Some medicines affect the way VFEND works, or VFEND may affect the way they work.

A list of the medicines that may affect VFEND is shown in the section ‘Taking other medicines with VFEND’. However, the medicines in the following list must not be taken during your VFEND treatment:

Take special care with VFEND:

Taking other medicines with VFEND:
Please tell your doctor or pharmacist if you are taking or have recently taken any other medicines, including those that are obtained without a prescription.

Some medicines, when taken at the same time as VFEND, may affect the way VFEND works or VFEND may affect the way they work. Tell your doctor if you are taking any of the following medicines, as VFEND must not be taken if you are already taking any of these medicines (See also Section 2 above ‘Do not take VFEND):

Tell your doctor if you are taking the following medicine, as treatment with VFEND at the same time should be avoided if possible:

Tell your doctor if you are taking either of the following medicines, as treatment with VFEND at the same time should be avoided if possible, and a dose adjustment of voriconazole may be required:

Tell your doctor if you are taking any of the following medicines, as a dose adjustment or monitoring may be required to check that the medicines and/ or VFEND are still having the desired effect:

effects such as nausea and menstrual disorders)

Before being treated with VFEND, tell your doctor if:

While being treated with VFEND:

Pregnancy and breast-feeding:
VFEND must not be used during pregnancy, unless indicated by your doctor. Effective contraception must be used in women of childbearing potential. Contact your doctor immediately if you become pregnant while being treated with VFEND.

VFEND must not be used during breast-feeding. Ask your doctor or pharmacist for advice before taking any medicine whilst breast-feeding.

Driving and using machines:
VFEND may cause blurring of vision or uncomfortable sensitivity to light. While affected, do not drive or operate any tools or machines. Tell your doctor if you experience this.

Important information about some of the ingredients of VFEND
Each vial of VFEND contains 217.6 mg of sodium per vial. This should be taken into consideration if you are on a strictly controlled sodium diet.

How is it used?

Always take VFEND exactly as your doctor has told you. You should check with your doctor if you are not sure.

Your doctor will determine your dose depending on your weight and the type of infection you have.

Your doctor may change your dose depending on your condition.

The usual dose for adults (including elderly patients) is as follows:
Intravenous

6 mg/kg every 12 hours for
Dose for the first 24 hours the
(Loading Dose) first 24 hours

4 mgkg twice a day Dose after the first 24 hours Maintenance Dose

Depending on your response to treatment, your doctor may decrease the dose to 3 mg/kg twice daily. The doctor may decide to decrease the dose if you have mild to moderate cirrhosis.

VFEND powder for solution for infusion will be reconstituted and diluted to the correct concentration by your hospital pharmacist or nurse. (Please refer to the end of this leaflet for further information)

This will be given to you by intravenous infusion (into a vein) at a maximum rate of 3 mg/kg per hour over 1 to 2 hours.

VFEND treatment will continue for as long as your doctor advises, however duration of treatment with VFEND powder for solution for infusion should be no more than 6 months.

Patients with a weakened immune system or those with difficult infections may require long term treatment to prevent the infection from returning.
You may be switched from the intravenous infusion to tablets once your condition improves.

If a dose of VFEND has been forgotten:
As you will be given this medicine under close medical supervision, it is unlikely that a dose would be missed. However tell your doctor or pharmacist if you think that a dose has been forgotten.

If you stop taking VFEND:
When VFEND treatment is stopped by your doctor you should not experience any effects. However if you were taking medicines containing ciclosporin or tacrolimus you must mention this to your doctor, as the dose will need to be adjusted.

If you have any further questions on the use of this product, ask your doctor.

What are possible side effects?

Like all medicines, VFEND can cause side effects, although not everybody gets them. If any side effects occur, most are likely to be minor and temporary. However, some may be serious and need medical attention.

Very common side effects (occurring in at least 1 in 10 patients) are:

-Visual disturbances (change in vision)
-Fever
-Rash
-Nausea, vomiting, diarrhoea
-Headache
-Swelling of the extremities
-Stomach pains.

Common side effects (occurring in at least 1 in 100 patients) are:

-Flu-like symptoms, sinusitis, chills, weakness
-Anaemia, low numbers of cells called platelets that help the blood to clot, low numbers of some types of white blood cells or of all types of blood cells, red or purple discoloration of the skin which may be caused by low platelet count , other blood cell changes
-Low blood sugar, low blood potassium
-Anxiety, depression, tingling, confusion, dizziness, agitation, trembling, hallucinations and other nervous symptoms
-Low blood pressure, inflammation of a vein (which may be associated with the formation of a blood clot)
-Breathing difficulty, chest pain, fluid accumulation in the lungs
-Jaundice, redness of the skin
-Swelling of the lips or face
-Allergic reactions (sometimes severe), including widespread blistering rash and skin peeling, severe skin reaction following exposure to light or sun
-Itchiness
-Hair loss
-Back pain
-Kidney failure, blood in the urine, changes in blood tests of kidney function
-Inflammation at injection sites
-Changes in blood tests of liver function

Uncommon side effects (occurring in at least 1 in 1,000 patients) are:

-Enlarged lymph glands (sometimes painful)
-Increase in a type of white blood cell which may be associated with allergic reaction, disorder of blood clotting system
-Heart rhythm problems including very fast heartbeat, very slow heartbeat, fainting -Depressed function of the adrenal gland
-Problem with coordination
-Swelling of the brain
-Double vision pain and inflammation of the eyes and eyelids, involuntary movement of the eye -Decreased sensitivity to touch
-Constipation, inflammation of upper small intestine, dyspepsia, pancreatitis, peritonitis -Gingivitis,
-Swelling and inflammation of the tongue
-Enlarged liver, hepatitis, liver failure, gallbladder disease, gallstones
-Joint pain
-Inflammation of the kidney, proteins in the urine -Abnormal electrocardiogram (ECG) -Blood chemistry changes

Rare side effects (occurring in at least 1 in 10,000 patients) are:

Reactions during the infusion have occurred uncommonly with VFEND (including flushing, fever, sweating, increased heart rate and shortness of breath). Your doctor may stop the infusion if this occurs.

As VFEND has been known to affect the liver and the kidney, your doctor should monitor the function of your liver and kidney by doing blood tests. Please advise your doctor if you have any stomach pains or if your stools have a different consistency.

If any of these side effects persist or are troublesome, please tell your doctor.

If any of the side effects gets serious or if you notice any side effects not listed in this leaflet, please tell your doctor or pharmacist.

How should it be stored?

Keep VFEND out of the reach and sight of children. Do not use VFEND after the expiry date which is stated on the label. The expiry date refers to the last day of the month.

Once reconstituted, VFEND should be used immediately, but if necessary may be stored for up to 24 hours at 2°C - 8°C (in a refrigerator). Reconstituted VFEND needs to be diluted with a compatible infusion solution first before it is infused. (Please refer to the end of this leaflet for further information).

Medicines should not be disposed of via wastewater or household waste. Ask your pharmacist how to dispose of medicines no longer required. These measures will help to protect the environment.

↑ back to table of contents ↑

For doctors

What is it?

VFEND contains the active substance voriconazole. It is available as white tablets, which contain 50 mg or 200 mg of voriconazole, as an oral suspension, which contains 40 mg/ml of voriconazole, and as a white powder to be made into a solution for infusion (drip into a vein).

What is it used for?

VFEND is an antifungal medicine. It is used for the treatment of patients (adults and children over the age of 2) with:

How is it used?

VFEND is given twice daily. The dosage of VFEND to use depends on the weight of the patient and on the presentation used; for the full information, please see the Package Leaflet. Patients need to receive a loading dose on the first day of treatment. The aim of the loading dose is to reach ‘steady state’ (stable) blood levels. The loading dose is then followed by a maintenance dose that can be adjusted according to the patient’s response. There is no need of a loading dose in children aged between 2 and 12 years.
Both the loading and the maintenance dose can be given by infusion or orally, using either the tablets or the suspension, but the use of the suspension is recommended in children aged between 2 and 12 years. The tablets and suspension are to be taken at least one hour before, or one hour following, a meal.

How does it work?

The active substance in VFEND, voriconazole, is an antifungal medicine that belongs to the group of the triazoles. It works by preventing the formation of ergosterol, which is an important part of fungal cell membranes. Without ergosterol, the fungus is killed or prevented from spreading. The list of fungi against which VFEND is active can be found in the Summary of Product Characteristics.

How has it been studied?

The study of VFEND in invasive aspergillosis involved 277 immunocompromised patients (their immune system was not working properly). VFEND was compared with amphotericin B (another antifungal medicine). The study of VFEND in candidaemia (370 patients) compared VFEND with a treatment of amphotericin B followed by fluconazole. VFEND has also been studied in serious refractory Candida infections (55 patients), in scedosporiosis (38 patients) and in fusariosis (21 patients) . Most patients receiving VFEND treatment for these rare infections did not tolerate or did not respond to prior treatment with other antifungal therapy. VFEND has also been studied in 61 children. The main measure of effectiveness in all studies was complete or partial response to treatment.

What benefits has it shown during the studies?

In invasive aspergillosis, the percentage of patients responding to treatment was higher with VFEND than with amphotericin B (53% versus 31%). The survival for voriconazole was significantly greater than that for amphotericin B. For candidaemia, the percentage of responders to VFEND treatment at the end of therapy was the same as for the comparator (72%). A successful outcome was seen in 24/55 (43.6%) subjects with serious refractory Candida infections. In most of these (15/24), the response was complete. In the treatment of scedosporiosis and fusariosis, the overall response was 28/59 patients.

What is the risk associated?

The most commonly reported side effects are visual disturbances, fever, rash, nausea, vomiting, diarrhoea, headache, and swelling of the extremities. Stomach pains and changes in stools should be reported to a doctor. For the full list of all side effects reported with VFEND, please see the Package Leaflet.
VFEND should not be used in people who may be hypersensitive (allergic) to voriconazole or any of the other ingredients. VFEND should not be used in patients who are taking any of the following medicines:

Why has it been approved?

The Committee for Medicinal products for Human Use (CHMP) decided that VFEND’s benefits are greater than its risks for treatment of serious fungal infections, especially in patients with life-threatening infection. They recommended that VFEND be given marketing authorisation.

Further information

The European Commission granted a marketing authorisation valid throughout the European Union, for VFEND to Pfizer Limited on 19 March 2002.

↑ back to table of contents ↑
 

Name

 

VFEND 200 mg powder for solution for infusion

 

Composition

 

Each ml contains 10 mg of voriconazole after reconstitution (see section 6.6) - once reconstituted further dilution is required before administration.
Each vial contains 200 mg of voriconazole.
Excipient: each vial contains 217.6 mg sodium
For a full list of excipients, see section 6.1.

 

Pharmaceutical Form

 

White lyophilised powder

 

Are you an Healthcare Professional? Access professional drug leaflets on Diagnosia.com!

 

以下是“全球医药”详细资料
Tags: 责任编辑:admin
】【打印繁体】【投稿】【收藏】 【推荐】【举报】【评论】 【关闭】 【返回顶部
分享到QQ空间
分享到: 
上一篇VFEND 50 mg film-coated tablets.. 下一篇VFEND 200 mg film-coated tablet..

相关栏目

最新文章

图片主题

热门文章

推荐文章

相关文章

广告位